Comparison of Humoral Response between Third and Fourth Doses of COVID-19 Vaccine in Hemodialysis Patients
Authors:
- Yoosun JooYJYoosun Joo
- Dae Kyu KimDKDae Kyu Kim
- Yun Gi JeonYJYun Gi Jeon
- Ah-Ra KimAKAh-Ra Kim
- Hyeon Nam DoHDHyeon Nam Do
- Soo-Young YoonSYSoo-Young Yoon
- Jin Sug KimJKJin Sug Kim
- Su Woong JungSJSu Woong Jung
- Hyeon Seok HwangHHHyeon Seok Hwang
- Ju-Young MoonJMJu-Young Moon
- Kyung Hwang JeongKJKyung Hwang Jeong
- Sang-Ho LeeSLSang-Ho Lee
Open Access
Abstract
Dialysis patients are more likely to die or become hospitalized from coronavirus disease 2019 (COVID-19). Currently, only a few studies have evaluated the efficacy of a fourth booster vaccination in hemodialysis (HD) patients and there is not enough evidence to recommend for or against a fourth booster vaccination. This study compared the humoral response and disease severity of patients on HD who received either three or four doses of COVID-19 vaccine. A total of 88 patients were enrolled. Humoral response to vaccination was measured by quantifying immunoglobulin G levels against the receptor binding domain of SARS-CoV-2 (anti-RBD IgG) at five different times and plaque reduction neutralization tests (PRNT) at two different times after vaccination over a period of 18 months. Antibody levels were measured at approximately two-month intervals after the first and second dose, then four months after the third dose, and then one to six months after the fourth dose of vaccine. PRNT was performed two months after the second and four months after the third dose of vaccine. We classified patients into four groups according to the number of vaccine doses and presence of COVID-19 infection. Severe infection was defined as hospital admission for greater than or equal to two weeks or death. There was no difference in antibody levels between naïve and infected patients except after a fourth vaccination, which was effective for increasing antibodies in infection-naïve patients. Age, sex, body mass index (BMI), dialysis vintage, and presence of diabetes mellitus (DM) did not show a significant correlation with antibody levels. Four patients who experienced severe COVID-19 disease tended to have lower antibody levels prior to infection. A fourth dose of SARS-CoV-2 vaccine significantly elevated antibodies in infection-naïve HD patients and may be beneficial for HD patients who have not been previously infected with SARS-CoV-2 for protection against severe infection.Keywords
This publication has 43 references indexed in Scilit:
- Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant RecipientsJournal of the American Society of Nephrology, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Time on previous renal replacement therapy is associated with worse outcomes of COVID-19 in a regional cohort of kidney transplant and dialysis patientsMedicine, 2021
- Minimizing the risk of COVID-19 among patients on dialysisNature Reviews Nephrology, 2020
- Leukocyte Toll-Like Receptor Expression in End-Stage Kidney DiseaseAmerican Journal of Nephrology, 2010
- Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine productionNephrology Dialysis Transplantation, 2009
- Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expressionNephrology Dialysis Transplantation, 2009
- Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal diseaseKidney International, 2007
- T‐cell activation follows Th1 rather than Th2 pattern in haemodialysis patientsNephrology Dialysis Transplantation, 2000
- Impaired Phagocytosis in Dialysis Patients: Studies on MechanismsAmerican Journal of Nephrology, 1991